I 
114TH CONGRESS 
1ST SESSION H. R. 3537 
To amend the Controlled Substances Act to clarify how controlled substance 
analogues are to be regulated, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
SEPTEMBER 17, 2015 
Mr. DENT (for himself, Mr. HIMES, Mr. MEEHAN, Mr. DOLD, Mr. TIBERI, 
Mr. COSTELLO of Pennsylvania, Mr. HANNA, Mr. THOMPSON of Pennsyl-
vania, Mr. ROGERS of Kentucky, Mr. MURPHY of Pennsylvania, Mr. 
BARLETTA, Ms. NORTON, Mr. LANCE, Mrs. COMSTOCK, Mr. KATKO, Ms. 
ROS-LEHTINEN, and Mr. JOLLY) introduced the following bill; which was 
referred to the Committee on Energy and Commerce, and in addition to 
the Committee on the Judiciary, for a period to be subsequently deter-
mined by the Speaker, in each case for consideration of such provisions 
as fall within the jurisdiction of the committee concerned 
A BILL 
To amend the Controlled Substances Act to clarify how con-
trolled substance analogues are to be regulated, and for 
other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Synthetic Drug Con-
trol Act of 2015’’. 
VerDate Sep 11 2014 
01:09 Sep 22, 2015
Jkt 049200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H3537.IH
H3537
SSpencer on DSK4SPTVN1PROD with BILLS
SEC. 2. CONTROLLED SUBSTANCE ANALOGUES. 
(a) EXPANSION OF DEFINITION.— 
(1) IN GENERAL.—Clauses (i), (ii), and (iii) of 
section 102(32)(A) of the Controlled Substances Act 
(21 U.S.C. 802(32)(A)) are amended by striking 
‘‘substantially’’ each place it appears. 
(2) 
RULE
OF
CONSTRUCTION.—Section 
102(32)(A) of the Controlled Substances Act (21 
U.S.C. 82(32)(A)) shall not be construed to require 
that a substance satisfy more than one of the 
clauses listed in such section 102(32)(A) to meet the 
definition of a controlled substance analogue. 
(b) LIMITATION ON TREATMENT AS CONTROLLED 
SUBSTANCES.—Section 203 of the Controlled Substances 
Act (21 U.S.C. 813) is amended by inserting before the 
period at the end the following: ‘‘for purposes of prohibi-
tions, restrictions, and other requirements with respect to 
manufacture, importation, distribution, and sale’’. 
SEC. 3. TREATMENT OF CERTAIN DESIGNER DRUGS AS 
SCHEDULE I CONTROLLED SUBSTANCES. 
(a) IN GENERAL.—Schedule I, as set forth in section 
202(c) of the Controlled Substances Act (21 U.S.C. 
812(c)) is amended by adding at the end the following: 
‘‘(e)(1) Unless specifically exempted or unless listed 
in another schedule, any material, compound, mixture, or 
preparation which contains any quantity of a substances 
VerDate Sep 11 2014 
01:09 Sep 22, 2015
Jkt 049200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H3537.IH
H3537
SSpencer on DSK4SPTVN1PROD with BILLS
listed in paragraphs (2) through (10), or which contains 
the salts, isomers, and salts of isomers thereof whenever 
the existence of such salts, isomers, and salts of isomers 
is possible within the specific chemical designation. 
‘‘(2) PHENYLALKYLAMINES.—The substances listed 
in 
this 
paragraph 
consist 
of 
the 
following 
phenylalkylamines: 
‘‘(A) 
2–(ethylamino)–1–(4-methylphenyl)–1- 
propanone. 
‘‘(B) 
1–(4-ethylphenyl)–2–(methylamino)–1- 
propanone. 
‘‘(C) 
1–(3-fluorophenyl)–2–(methylamino)–1- 
propanone. 
‘‘(D) 
1–(4-fluorophenyl)–2–(methylamino)–1- 
propanone. 
‘‘(E) 1–(4-methoxyphenyl)–2–(methylamino)–1- 
propanone. 
‘‘(F) 
2–(ethylamino)–1–(4-methoxyphenyl)–1- 
propanone. 
‘‘(G) 
1–(2-naphthalenyl)–2–(1-pyrrolidinyl)–1- 
pentanone. 
‘‘(H) 1–(1,3-benzodioxol-5-yl)–2–(ethylamino)– 
1-propanone. 
‘‘(I) 1–(1,3-benzodioxol-5-yl)–2–(methylamino)– 
1-butanone. 
VerDate Sep 11 2014 
01:09 Sep 22, 2015
Jkt 049200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H3537.IH
H3537
SSpencer on DSK4SPTVN1PROD with BILLS
‘‘(J) 
1–(1,3-benzodioxol-5-yl)–2– 
(methylamino)–1-pentanone. 
‘‘(K) 2–(ethylamino)–1-phenyl-1-propanone. 
‘‘(L) 1-phenyl-2–(1-pyrrolidinyl)–1-propanone. 
‘‘(M) 1–(4-methylphenyl)–2–(1-pyrrolidinyl)–1- 
propanone. 
‘‘(N) 1–(4-methoxyphenyl)–2–(1-pyrrolidinyl)– 
1-propanone. 
‘‘(O) 
1–(1,3-benzodioxol-5-yl)–2–(1- 
pyrrolidinyl)–1-propanone. 
‘‘(P) 1-phenyl-2–(1-pyrrolidinyl)–1-pentanone. 
‘‘(Q) 2-amino-1–(4-fluoro)–1-propanone. 
‘‘(R) 2–(methylamino)–1-phenyl-1-pentanone. 
‘‘(S) 
2–(ethylamino)–1–(4-ethylphenyl)–1- 
propanone. 
‘‘(T) 2–(dimethylamino)–1-phenyl-1-propanone. 
‘‘(U) 
1–(1,3-benzodioxol-5-yl)–2–(1- 
pyrrolidinyl)–1-butanone. 
‘‘(V) 
1–(methylphenyl)–2–(1-pyrrolidinyl)–1- 
hexanone. 
‘‘(W) 2–(methylamino)–1-phenyl-1-butanone. 
‘‘(X) 2–(methylamino)–1-p-tolyl-1-butanone. 
‘‘(Y) 1–(4-methylphenyl)–2–(1-pyrrolidinyl)–1- 
butanone. 
VerDate Sep 11 2014 
01:09 Sep 22, 2015
Jkt 049200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H3537.IH
H3537
SSpencer on DSK4SPTVN1PROD with BILLS
‘‘(Z) 1–(3,4-dimethylphenyl)–2–(methylamino)– 
1-propanone. 
‘‘(AA) 1-phenyl-2–(1-pyrrolidinyl)–1-butanone. 
‘‘(BB) 
1–(1,3-benzodioxol-5-yl)–2– 
(dimethylamino)–1-propanone. 
‘‘(CC) 1–(4-methylphenyl)–2–(benzylamino)–1- 
propanone. 
‘‘(DD) 
1–(1-naphthy)–2–(1-pyrrolidinyl)–1- 
pentanone. 
‘‘(EE) 
1–(1,3-benzodioxol-5-yl)–2– 
(benzylamino)–1-propanone. 
‘‘(FF) 
1–(1,3-benzodioxol-5-yl)–2– 
(benzylamino)–1-butanone. 
‘‘(GG) 1–(1,3-benzodioxol)–2-[hydroxy(methyl)- 
amino]-1-propanone. 
‘‘(HH) 
1–(1,3-benzodioxol-5-yl)–2– 
(dimethylamino)–1-butanone. 
‘‘(II) 
2–(ethyl(methyl)amino)–1-phenyl-buta-
none. 
‘‘(JJ) 1–(4-bromophenyl)–2–(methylamino)–1- 
propanone. 
‘‘(KK) 
2–(ethyl(methyl)amino-1-phenyl-1- 
propanone. 
‘‘(LL) 2–(methylamino)–1-m-tolyl-1-propanone. 
VerDate Sep 11 2014 
01:09 Sep 22, 2015
Jkt 049200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H3537.IH
H3537
SSpencer on DSK4SPTVN1PROD with BILLS
‘‘(MM) 2–(pyrrolidin-1-yl)–1–(thiophen-2-yl)–1- 
pentanone. 
‘‘(NN) 1–(4-fluorophenyl)–2–(methylamino)–1- 
butanone. 
‘‘(OO) 
1–(4-methoxyphenyl)–2–(pyrrolidin-1- 
yl)–1-butanone. 
‘‘(PP) 1–(4-ethylphenyl)–2–(pyrrolidin-1-yl)–1- 
butanone. 
‘‘(QQ) 
1–(4-methoxy-3-methylphenyl)–2– 
(methylamino)–1-propanone. 
‘‘(RR) 
2–(ethylamino)–1–(3-methylphenyl)–1- 
propanone. 
‘‘(SS) 2-amino-(1H-indol-5-yl)propan-1-one. 
‘‘(TT) 1-phenyl-2–(piperidin-1-yl)butan-1-one. 
‘‘(UU) 
2-methylamino-1–(2,4,5- 
trimethylphenyl)-propan-1-one). 
‘‘(VV) 1-phenyl-2–(pyrrolidin-1-yl)heptan-1-one. 
‘‘(WW) 1-phenyl-2–(pyrrolidin-1-yl)hexan-1-one. 
‘‘(XX) 
1–(4-fluorophenyl)–2–(pyrrolidin-1- 
yl)pentan-1-one. 
‘‘(YY) 
1–(benzo[d][1,3]dioxol-5-yl)–2– 
(dimethylamino)pentan-1-one. 
‘‘(ZZ) 
1–(2-fluorophenyl)–N-methyl-propan-2- 
amine. 
‘‘(AAA) 1–(2-fluorophenyl)-propan-2-amine. 
VerDate Sep 11 2014 
01:09 Sep 22, 2015
Jkt 049200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H3537.IH
H3537
SSpencer on DSK4SPTVN1PROD with BILLS
‘‘(BBB) 1–(3-fluorophenyl)- propan-2-amine. 
‘‘(CCC) 1–(3-fluorophenyl)–N-methyl-propan-2- 
amine. 
‘‘(DDD) 1–(4-fluorophenyl)- propan-2-amine. 
‘‘(EEE) 1–(4-fluorophenyl)–N-methyl-propan-2- 
amine. 
‘‘(FFF) 1–(4-methylphenyl)propan-2-amine. 
‘‘(GGG) 
N-ethyl-N-methyl-1-phenylpropan-2- 
amine. 
‘‘(HHH) 1–(benzofuran-4-yl)propan-2-amine. 
‘‘(III) 1–(benzofuran-5-yl) propan-2-amine. 
‘‘(JJJ) 1–(2,3-dihydrobenzofuran-5-yl)proan-2- 
amine. 
‘‘(KKK) 1–(benzofuran-6-yl)- propan-2-amine. 
‘‘(LLL) 1–(2,3-dihydrobenzofuran-6-yl)proan-2- 
amine. 
‘‘(MMM) 
1–(4-methoxyphenyl)–N-methyl- 
propan-2-amine. 
‘‘(NNN) N,N-dimethyl-1-phenylpropan-2-amine. 
‘‘(OOO) 1–(2,3-dihydro-1H-inden-5-yl)propan- 
2-amine. 
‘‘(PPP) 
5,6,7,8-tetrahydrobenzo[1,3]- 
benzodioxol-7-amine. 
‘‘(QQQ) 
a-methyl-4–(methylthio)-benzene- 
ethanamine. 
VerDate Sep 11 2014 
01:09 Sep 22, 2015
Jkt 049200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H3537.IH
H3537
SSpencer on DSK4SPTVN1PROD with BILLS
‘‘(RRR) 1–(4-chlorophenyl)-propan-2-amine. 
‘‘(SSS) 
1–(2,4,6-trimethoxyphenyl)-propan-2- 
amine. 
‘‘(TTT) 
1–(2,4,5-trimethoxyphenyl)-propan-2- 
amine. 
‘‘(UUU) 
1–(2,5-dimethylphenyl)-propan-2- 
amine. 
‘‘(VVV) 
1–(3,4-dimethylphenyl)-propan-2- 
amine. 
‘‘(WWW) 
N–(1-phenylpropan-2-yl)propan-1- 
amine. 
‘‘(XXX) 4–(2-aminopropyl)phenol. 
‘‘(YYY) 
3,4-methylenedioxy-N,N-dimethyl-am-
phetamine. 
‘‘(ZZZ) N-ethyl-1–(4-methoxyphenyl)propan-2- 
amine. 
‘‘(AAAA) 1–(benzofuran-5-yl)–N-methylpropan- 
2-amine. 
‘‘(BBBB) 
6,7-dihydro-5H-inden[5,6- 
d][1,3]dioxol-6-amine. 
‘‘(CCCC) 5-iodo-2,3-dihydro-1H-inden-2-amine. 
‘‘(DDDD) 2,3-dihydro-1H-inden-2-amine. 
‘‘(EEEE) 5-methoxy-6-methyl-2,3-dihydro-1H- 
inden-2-amine. 
VerDate Sep 11 2014 
01:09 Sep 22, 2015
Jkt 049200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H3537.IH
H3537
SSpencer on DSK4SPTVN1PROD with BILLS
‘‘(FFFF) 
N-methyl-6,7-dihydro-5H- 
cyclopenta[1,3]-benzodioxol-6-amine. 
‘‘(GGGG) 
N-methyl-2,3-dihydro-1H-inden-2- 
amine. 
‘‘(HHHH) 
2-[4–(2-fluoroethylthio)–2,5- 
dimethoxyphenyl]ethanamine. 
‘‘(IIII) 
8-bromo-2,3,6,7-tetrahydro-benzo[1,2- 
b;4,5-b’]difuran-4-ethanamine. 
‘‘(JJJJ) 
4-iodo-2,5-dimethoxy-N-[(2- 
methoxyphenyl)-methyl-benzene-ethamine. 
‘‘(KKKK) 
2–(4-chloro-2,5-dimethoxyphenyl)– 
N–(2-methoxybenzyl)-ethanamine. 
‘‘(LLLL) 
2–(2,5-dimethoxy-3,4- 
dimethylphenyl)-ethanamine. 
‘‘(MMMM) 2–(4-methyl-2,5-dimethoxyphenyl)– 
N–(2-methoxybenzyl)-ethanamine. 
‘‘(NNNN) 2–(4-ethyl-2,5-dimethoxyphenyl)–N– 
(2-methoxybenzyl)-ethanamine. 
‘‘(OOOO) 
2–(2,5-dimethoxy-3,4- 
dimethylphenyl)–N–(2-methoxybenzyl)-ethanamine. 
‘‘(PPPP) 
2–(2,5-dimethoxyphenyl)–N–(2-me-
thoxybenzyl)-ethanamine. 
‘‘(QQQQ) 
2–(4-bromo-2,5-dimethoxyphenyl)– 
N–(2-methoxybenzyl)-ethanamine. 
VerDate Sep 11 2014 
01:09 Sep 22, 2015
Jkt 049200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H3537.IH
H3537
SSpencer on DSK4SPTVN1PROD with BILLS
‘‘(RRRR) 
2–(2,5-dimethoxyphenyl-4-nitro)–N- 
[(2-methoxyphenyl)methyl]-ethanamine. 
‘‘(SSSS) 
1–(4-iodo-2,5- 
dimethoxyphenyl)propan-2-amine. 
‘‘(TTTT) 
1–(4-bromofuro[2,3-f]benzofuran-8- 
yl)propan-2-amine. 
‘‘(UUUU) 
1–(4-chloro-2,5- 
dimethoxyphenyl)propan-2-amine. 
‘‘(VVVV) 
1–(4-bromo-2,3,6,7- 
terahydrofuro[2,3-f]benzofuran-8-yl)propan-2-amine. 
‘‘(WWWW) 
(2,5-dimethoxyphenyl)-propan-2- 
amine. 
‘‘(XXXX) 
1-[4–(ethylthio)–2,5- 
dimethoxyphenyl)propan-2-amine. 
‘‘(YYYY) 
1–(4-ethoxy-2,5- 
dimethoxyphenyl)propan-2-amine. 
‘‘(ZZZZ) 
1-[2,5-dimethoxy-4– 
(propylthio)phenyl]propan-2-amine. 
‘‘(AAAAA) 
1–(4-ethyl-2,5- 
dimethoxyphenyl)propan-2-amine. 
‘‘(BBBBB) N-benzyl-2-phenylethanamine. 
‘‘(CCCCC) N,N-dimethyl-2-phenylethanamine. 
‘‘(DDDDD) 6-chloro-aminotetralin. 
‘‘(EEEEE) 2-phenyl-propan-1-amine. 
‘‘(FFFFF) 2-phenethylamine. 
VerDate Sep 11 2014 
01:09 Sep 22, 2015
Jkt 049200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H3537.IH
H3537
SSpencer on DSK4SPTVN1PROD with BILLS
‘‘(GGGGG) 
1-methylamino-1–(3,4- 
methylendioxy-phenyl)propane. 
‘‘(HHHHH) 
N-methyl-3- 
phenylbicyclo[2.2.1]heptan-2-amine. 
‘‘(IIIII) 1–(2-methoxyphenyl)–N-methylpropan- 
2-amine. 
‘‘(JJJJJ) 
2–(4–(allyloxy)–3,5- 
dimethoxyphenyl)ethanamine. 
‘‘(KKKKK) 4-methylhexan-2-amine. 
‘‘(LLLLL) 
4-methyl-5-phenyl-2-amino- 
oxazoline. 
‘‘(MMMMM) N-methyl-1-thiophen-2-yl)propan- 
2-amine. 
‘‘(NNNNN) 
(3-dimethylamino-2,2- 
dimethylpropyl)–4-aminobenzoate. 
‘‘(OOOOO) 
1–(4-fluorophenyl)–2– 
(methylamino)-propan-1-ol. 
‘‘(PPPPP) 4-methyl-5-p-tolyl-4,5-dihydrooxazol- 
2-amine. 
‘‘(QQQQQ) 1-phenyl-2–(pyrrolidin-1-yl)propan- 
1-ol. 
‘‘(3) CANNABIMIMETIC AGENTS.—The substances 
listed in this paragraph consist of the following 
cannabimimetic agents: 
VerDate Sep 11 2014 
01:09 Sep 22, 2015
Jkt 049200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H3537.IH
H3537
SSpencer on DSK4SPTVN1PROD with BILLS
‘‘(A) 
(4-ethyl-1-naphthalenyl)(1-pentyl-1H- 
indol-3-yl)methanone. 
‘‘(B) 2–(2-methylphenyl)–1–(1-pentyl-1H-indol- 
3-yl)-ethanone. 
‘‘(C) 1-[1–(2-cyclohexylethyl)–1H-indol-3-yl]-2– 
(2-methoxyphenyl)-ethanone. 
‘‘(D) 
[1–(5-fluoropentyl)–1H-indol-3-yl](2- 
iodophenyl)methanone. 
‘‘(E) 
(2-methyl-1-[(1-methylpiperidin-2- 
yl)methyl]-6-nitro-1H-indol-3-yl)methanone. 
‘‘(F) (1-butyl-1H-indol-3-yl)(4-methoxyphenyl)- 
methanone. 
‘‘(G) 
(1-butyl-1H-indol-3-yl)(4- 
methylnaphthalen-1-yl)methanone. 
‘‘(H) 
[1–(5-fluoropentyl)–1H-indol-3-yl](4- 
methyl-1-naphthalenyl)-methanone. 
‘‘(I) 
[1-[(1-methyl-2-piperidinyl)methyl]-1H- 
indol-3-yl]-1-naphthalenyl-methanone. 
‘‘(J) 
3–(4-methoxyphenyl)–2-methyl-1-[(2–(4- 
morpholinyl)ethyl)–1H-indol-3-yl]-methanone. 
‘‘(K) 
[2,3-dihydro-5-methyl-3–(4- 
morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin- 
6-yl]-1-naphthalenyl- methanone. 
‘‘(L) 
2–(3-methoxyphenyl)–1–(1-pentyl-1H- 
indol-3-yl)-ethanone. 
VerDate Sep 11 2014 
01:09 Sep 22, 2015
Jkt 049200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H3537.IH
H3537
SSpencer on DSK4SPTVN1PROD with BILLS
‘‘(M) 
(2-iodophenyl)[1-[(1-methyl-2- 
piperidinyl)methyl]-1H-indol-3-yl]-methanone. 
‘‘(N) 
[1-[(1-methyl-2-piperdinyl)methyl]-1H- 
indol-3-yl]tricycle[3.3.1.13,7]dec-1-yl-methanone. 
‘‘(O) 
1-naphthalenyl(1-propyl-1H-indol-3-yl)- 
methanone. 
‘‘(P) 
5-[3–(1-naphthoyl)–1H-indole-1- 
yl]pentanenitrile. 
‘‘(Q) 
3–(1-naphthenylmethyl)–1-pentyl-1H- 
indole. 
‘‘(R) 
(2-methyl-1-propyl-1H-indol-3-yl)–1- 
napthalenyl-methanone. 
‘‘(S) 
1-naphthalenyl[1–(4-penten-1-yl)–1H- 
indol-3-yl]-methanone. 
‘‘(T) 
(4-bromonaphthalen-1-yl)(1-pentyl-1H- 
indol-3-yl)methanone. 
‘‘(U) 
(4-fluoronaphthalen-1-yl)(1-pentyl-1H- 
indol-3-yl)methanone. 
‘‘(V) 
(2-methyl-1-phenyl-1H-indol-3-yl)–1- 
naphthalenyl-methanone. 
‘‘(W) 2–(2-chlorophenyl)–1–(1-pentyl-1H-indol- 
3-yl)-ethanone. 
‘‘(X) 
[1–(5-chloropentyl)–1H-indol-3-yl](2- 
iodophenyl)-methanone. 
VerDate Sep 11 2014 
01:09 Sep 22, 2015
Jkt 049200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H3537.IH
H3537
SSpencer on DSK4SPTVN1PROD with BILLS
‘‘(QQQQ) 
(1–(4-fluorobenzyl)–1H-indol-3- 
yl)(napthalen-1-yl)methanone. 
‘‘(RRRR) methyl 2–(1–(4-fluorobenzyl)–1H-in-
dazole-3-carboxamido)–3,3-dimethylbutanoate. 
‘‘(SSSS) quinolin-8-yl 1–(4-fluorobenzyl)–1H- 
indazole-3-carboxylate. 
‘‘(TTTT) 
N–(adamantan-1-yl)–1–(4- 
fluorobenzyl)–1H-indazole-3-carboxamide. 
‘‘(UUUU) N–(1-amino-3-methyl-1-oxobutan-2- 
yl)–1–(5-fluoropentyl)–1H-indole-3-carboxamide. 
‘‘(VVVV) 
2-[(1S,3R)–3-hydroxycyclohexyl]-5– 
(2-methylheptyl-2-yl)phenol. 
‘‘(WWWW) 2-[(1S,3R)–3-hydroxycyclohexyl]-5– 
(2-methyldodecanyl-2-yl)phenol. 
‘‘(XXXX) 
3-hydroxy-2[3-methyl-6–(1- 
methylethyenyl)–2-cyclohexen-1-yl]-5-pentyl-2,5- 
cyclohexadiene-1,4-dione. 
‘‘(YYYY) 
4-[4–(1,1-dimethylheptyl)–2,6- 
dimethoxyphenyl]-6,6-dimethyl-bicyclo[3.1.1]hept-2- 
ene-2-methanol. 
‘‘(ZZZZ) 
1-naphthalenyl[4–(pentylox)–1- 
naphthalenyl]-methanone. 
‘‘(AAAAA) 3–(2–(hydroxymethyl)–2,3-dihydro- 
1H-inden-4-yloxy)phenyl 
4,4,4-trifluorobutane-1- 
sulfonate. 
VerDate Sep 11 2014 
01:09 Sep 22, 2015
Jkt 049200
PO 00000
Frm 00020
Fmt 6652
Sfmt 6201
E:\BILLS\H3537.IH
H3537
SSpencer on DSK4SPTVN1PROD with BILLS
‘‘(BBBBB) N–(benzo[1,3]dioxol-5-ylmethyl)–7- 
methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3- 
carboxamide. 
‘‘(CCCCC) 
N-[3–(2-methoxyethyl)–4,5- 
dimethylthiazol-2-ylidene]-2,2,3,3- 
tetramethylcyclopropane-carboxamide. 
‘‘(DDDDD) 5-chloro-3-ethyl-N-[4–(piperidin-1- 
yl)phenethyl)–1H-indole-2-carboximide. 
‘‘(EEEEE) N-[4–(dimethylamino)phenethyl]-3- 
ethyl-5-fluoro-1H-indole-2-carboximide. 
‘‘(FFFFF) 
N–(1-benzylpyrrolidin-3-yl)–5- 
chloro-3-ethyl-1H-indole-2-carboxamide. 
‘‘(GGGGG) 
[5–(2-fluorophenyl)–1-pentyl-1H- 
pyrrol-3-yl](naphthalene-1-yl)methanone. 
‘‘(HHHHH) (3’-(aminocarbonyl)[1,1’-biphenyl]- 
3-yl)-cyclohexyl-carbamate. 
‘‘(IIIII) 5–(biphenyl-4-ylmethyl)–N,N-dimethyl- 
1H-tetrazole-1-carboxamide. 
‘‘(JJJJJ) 
6-methyl-2–(p-tolylamino)–4H- 
benzo[d][1,3]oxazin-4-one. 
‘‘(KKKKK) [1,1’-biphenyl]-3-yl-carbamic acid, 
cyclohexyl ester. 
‘‘(LLLLL) 4-hydroxy-N–(4-hydroxyphenethyl)– 
3–(pentylamino)-benzamide. 
VerDate Sep 11 2014 
01:09 Sep 22, 2015
Jkt 049200
PO 00000
Frm 00021
Fmt 6652
Sfmt 6201
E:\BILLS\H3537.IH
H3537
SSpencer on DSK4SPTVN1PROD with BILLS
‘‘(MMMMM) 
3’-carbamoyl-6-hydroxy-[1,1’- 
biphenyl]-3-yl cyclohexylcarbamate. 
‘‘(4) ARYLCYCLOHEXAMINES.—The substances listed 
in 
this 
paragraph 
consist 
of 
the 
following 
arylcyclohexamines: 
‘‘(A) 1–(3-methoxyphenyl)–N-propylcyclohexan- 
amine. 
‘‘(B) 
2–(ethylamino)–2–(3- 
methoxyphenyl)cyclohexanone. 
‘‘(C) 1-phenylcyclohexan-amine. 
‘‘(D) 
1-[1–(benzothiophen-2- 
yl)cyclohexyl]piperidine. 
‘‘(E) 1–(1-p-tolylcyclohexyl)-piperidine. 
‘‘(F) 1–(4-methoxyphenyl)–N-propylcyclohexan- 
amine. 
‘‘(G) 1-[1–(4-methoxyphenyl)cyclohexyl]-piper-
idine. 
‘‘(H) 1-[1–(3-methoxyphenyl)cyclohexyl]-piper-
idine. 
‘‘(I) 1-phenyl-N-propylcyclohexanamine. 
‘‘(J) 
N–(2-methoxyethyl)–1-phenylcyclohexan- 
amine. 
‘‘(K) 
N–(2-ethoxyethyl)–1-phenylcyclohexan- 
amine. 
VerDate Sep 11 2014 
01:09 Sep 22, 2015
Jkt 049200
PO 00000
Frm 00022
Fmt 6652
Sfmt 6201
E:\BILLS\H3537.IH
H3537
SSpencer on DSK4SPTVN1PROD with BILLS
‘‘(L) N–(3-methoxypropyl)–1-phenylcyclohexan- 
amine. 
‘‘(M) 3-[1–(piperidin-1-yl)cyclohexyl]-phenol. 
‘‘(N) 
2–(methoxyphenyl)–2– 
(methylamino)cyclohexanone. 
‘‘(O) N-ethyl-1–(thiophen-2-yl)cyclohexanamine. 
‘‘(P) 
(2–(2-chlorophenyl)–2–(ethylamino)- 
cyclohexanone). 
‘‘(5) TRYPTAMINES.—The substances listed in this 
paragraph consist of the following tryptamines: 
‘‘(A) 2–(1H-indol-3-yl)–N-methyl-ethanamine. 
‘‘(B) 
N–(2–(1H-indol-3-yl)ethyl-N- 
methylpropan-2-amine. 
‘‘(C) 
N-[2–(1H-indol-3-yl)ethyl]-N- 
isopropylpropan-2-amine. 
‘‘(D) N,N-dipropyl-1H-indole-3-ethanamine. 
‘‘(E) 3-[2–(diethylamino)ethyl]-1H–4yl acetate. 
‘‘(F) 3–(2-[isopropyl(methyl)amino]ethyl)–1H- 
indol-4-ol. 
‘‘(G) 3-[2–(bis[1-methylethyl]amino)ethyl]-1H- 
indol-4-ol acetate. 
‘‘(H) 3–(2-[isopropyl(methyl)amino]ethyl)–1H- 
indol-4-ol acetate. 
‘‘(I) 
3-[2–(dimethylamino)ethyl]-1H-indol-4-yl 
acetate. 
VerDate Sep 11 2014 
01:09 Sep 22, 2015
Jkt 049200
PO 00000
Frm 00023
Fmt 6652
Sfmt 6201
E:\BILLS\H3537.IH
H3537
SSpencer on DSK4SPTVN1PROD with BILLS
‘‘(J) 
4-hydroxy-N,N-diethyl-1H-indole- 
ethanamine. 
‘‘(K) 
4-methoxy-N,N-dimethyl-1H-indole-3- 
ethanamine. 
‘‘(L) 3–(2–(diisopropylamino)ethyl)–1H-indol-4- 
ol. 
‘‘(M) 3-[2–(ethyl[methyl]amino)ethyl]-1H-indol- 
4-ol. 
‘‘(N) 3-[2–(ethyl[methyl]amino)ethyl]-1H-indol- 
4-yl acetate. 
‘‘(O) 3–(2–(dipropylamino)ethyl)–1H-indol-4-ol. 
‘‘(P) 
3-[2–(dipropylamino)ethyl]-1H-indol-4-yl 
acetate. 
‘‘(Q) 4-acetoxy-N,N-di-2-propen-1-yl-1H-indole- 
3-ethanamine. 
‘‘(R) 
5-methoxy-N,N-di-2-propen-1-yl-1H- 
indole-3-ethanamine. 
‘‘(S) 3–(2–(dimethylaminoethyl)–1H-indol-5-ol. 
‘‘(T) 
2–(5-methoxy-1H-indol-3-yl)–N,N- 
dimethylethanamine. 
‘‘(U) 
N-[2–(5-methoxy-1H-indol-3-yl)ethyl]-N- 
methylpropyl. 
‘‘(V) 
1–(5-methoxy-1H-indol-3-yl)propan-2- 
amine. 
VerDate Sep 11 2014 
01:09 Sep 22, 2015
Jkt 049200
PO 00000
Frm 00024
Fmt 6652
Sfmt 6201
E:\BILLS\H3537.IH
H3537
SSpencer on DSK4SPTVN1PROD with BILLS
‘‘(W) 3-[2–(dimethylamino)-ethyl]-1H-indol-5-yl 
acetate. 
‘‘(X) 
N-[2–(5-methoxy-1H-indol-3-yl)ethyl]-N- 
propylpropan-1-amine. 
‘‘(Y) 
N,N-diethyl-2–(5-methoxy-1H-indol-3- 
yl)ethanamine. 
‘‘(Z) 
N-ethyl-2–(5-methoxy-1H-indol-3-yl)–N- 
methyl-ethanamine. 
‘‘(6) BENZYLPIPERIDINES.—The substances listed in 
this paragraph consist of the following benzylpiperidines: 
‘‘(A) 2–(diphenylmethyl)-piperidine. 
‘‘(B) 2-benzhydrylpyrrolidine. 
‘‘(C) a,a-diphenyl-(pyrrolidin-2-yl)methanol. 
‘‘(D) 
methyl 
2–(3,4-dichlorophenyl)–2– 
(piperdin-2-yl)acetate. 
‘‘(E) methyl 2–(3-chlorophenyl)–2–(piperidin-2- 
yl)acetate. 
‘‘(F) methyl 2–(piperidin-2-yl)–2-p-tolylacetate. 
‘‘(G) methyl 2–(4-fluorophenyl)–2–(piperidin-2- 
yl)acetate. 
‘‘(H) ethyl 2-phenyl-2–(piperidin-2-yl)acetate. 
‘‘(7) BENZODIAZEPINES.—The substances listed in 
this paragraph consist of the following benzodiazepines: 
‘‘(A) 
4–(2-chlorophenyl)–2-ethyl-9-methyl-6H- 
thieno-[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine. 
VerDate Sep 11 2014 
01:09 Sep 22, 2015
Jkt 049200
PO 00000
Frm 00025
Fmt 6652
Sfmt 6201
E:\BILLS\H3537.IH
H3537
SSpencer on DSK4SPTVN1PROD with BILLS
‘‘(B) 
7-bromo-5–(2-chlorophenyl)–1H- 
benzo[e][1,4]diazepin-2(3H)-one. 
‘‘(C) 
8-bromo-1-methyl-6-phenyl-4H- 
[1,2,4]triazolo[4,3a][1,4]benzodiazepine. 
‘‘(D) 
3-methyl-6-[3– 
(trifluoromethyl)phenyl][1,2,4]triazol[4,3- 
b]pyridazine. 
‘‘(E) 6–(5-chloro-2-pyridyl)–6,7-dihydro-7-oxo- 
5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1- 
carboxylate. 
‘‘(8) OPIOIDS AND OPIOID-LIKE SUBSTANCES.—The 
substances listed in this paragraph consist of the following 
opioids and opioid-like substances: 
‘‘(A) 
2–(1,3-dimethoxybuta-1,3-dien-2-yl)–3- 
ethyl-8-methoxy-1,2,3,4,6,7,12,12b- 
octahydroindolo[2,3-a]quin olizine. 
‘‘(B) (2a,4aR,6aR,7R,9S,10aS10bR)-methyl-9- 
acetoxy-2–(furan-3-yl)–6a,10b-dimethyl-4,10- 
dioxododecahydro-1 
H-benzo[f]isochromene-7- 
carboxylate. 
‘‘(C) 
3,4-dichloro-N–([1– 
(dimethylamino)cyclohexyl]methyl)benzamide. 
‘‘(D) 
3-[2–(amino-1-methylethyl)–1- 
hydroxycyclohexyl]-phenol. 
‘‘(E) 4,5-epoxy-17-methylmorphinan-3-ol. 
VerDate Sep 11 2014 
01:09 Sep 22, 2015
Jkt 049200
PO 00000
Frm 00026
Fmt 6652
Sfmt 6201
E:\BILLS\H3537.IH
H3537
SSpencer on DSK4SPTVN1PROD with BILLS
‘‘(F) 
N-phenyl-N-[1–(2-phenethyl)–4- 
piperidinyl] acetamide. 
‘‘(G) 
N–(1-benzylpiperidin-4-yl)–N–(x- 
fluorophenyl)-butanamide. 
‘‘(H) 2-methyl-N-phenyl-N-[1–(1-phenylpropan- 
2-yl)piperidin-4-yl]propanamide. 
‘‘(I) 
N–(1-phenethylpiperidin-4-yl)–N- 
phenylbutyramide. 
‘‘(J) 
1-cyclohexyl-4–(1,2-diphenylethyl)-piper-
azine. 
‘‘(K) 
N-phenyl-N–(1–(2–(thiophen-2- 
yl)ethyl)piperidin-4-yl)acetamide. 
‘‘(L) 
4-chloro-N–(1-phenethylpiperidin-2- 
ylidene)benzenesulfonamide. 
‘‘(M) 
4-chloro-N–(1–(4- 
nitrophenethyl)piperidin-2- 
ylidene)benzenesulfonamide. 
‘‘(9) PIPERAZINES.—The substances listed in this 
paragraph consist of the following piperazines: 
‘‘(A) 1,4-dibenzylpiperazine. 
‘‘(B) 
1–(4-bromo-2,5-dimethoxybenzyl)-piper-
azine. 
‘‘(C) 1–(4-fluorophenyl)-piperazine. 
‘‘(D) 1–(2-methoxyphenyl)-piperazine. 
‘‘(E) 1–(4-chlorophenyl)-piperazine. 
VerDate Sep 11 2014 
01:09 Sep 22, 2015
Jkt 049200
PO 00000
Frm 00027
Fmt 6652
Sfmt 6201
E:\BILLS\H3537.IH
H3537
SSpencer on DSK4SPTVN1PROD with BILLS